Akeso Confident of Cancer Drug's FDA Approval Odds

Chinese biopharmaceutical firm Akeso’s CFO, Bing Wang, says he feels “pretty good” about the chances of receiving approval from US regulators for ivonescimab, the company’s key cancer drug developed in partnership with US-based Summit Therapeutics. Wang speaks exclusively on Bloomberg: The China Show from San Francisco, where the marquee industry event hosted by JPMorgan is taking place. (Source: Bloomberg)